Sentinel lymph node biopsy in patients with thin melanoma: Occurrence of nodal metastases and its prognostic value

European Journal of Dermatology

Volumn 20, Issue 1, 2010, Pages 30-34

  Vermeeren, Lenka ^a   Van Der Ent, Fred ^a   Sastrowijoto, Prapto ^a   Hulsewé, Karel ^a  

^a Sittard Geleen Heerlen   (Netherlands)

Author keywords

Melanoma; Sentinel lymph node biopsy; Staging; Thin melanoma

Indexed keywords

DISULFINE BLUE; NANOCOLL TC 99M;

ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; PROGNOSIS; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 76749107429     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.0837     Document Type: Article

References (38)

1. Gershenwald JE, Thompson W, Mansfield PF, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83.
2. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17.
3. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol 2008; 15: 670-3.
4. Thomas JM. Sentinel lymph node biopsy in malignant melanoma. BMJ 2008; 336: 902-3.
5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
6. Agnese DM, Abdessalam SF, Burak Jr. WE, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003; 134: 542-7.
7. Statius Muller MG, van Leeuwen PA, van Diest PJ, Vuylsteke RJ, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001; 11: 303-7.
8. Hershko DD, Robb BW, Lowy AM, Ahmad SA, Ramadas GH, Soldano DA. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 2006; 93: 279-85.
9. Koskivuo I, Suominen E, Niinikoski J, Talve L. Sentinel node metastasectomy in thin
10. Lowe JB,Hurst E,Moley JF,Cornelius LA. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003; 139: 617-21.
11. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman 3rd JJ. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006; 13: 927-32.
12. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness
13. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13: 302-9.
14. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, Sixth Edition. New York: Springer-Verlag, 2002.
15. Vaquerano J, Kraybill WG, Driscoll DL, Cheney R, Kane 3rd JM. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006; 13: 198-204.
16. Bedrosian I, Faries MB, Guerry 4th D, Elenitsas R, Schuchter L, Mick R. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7: 262-7.
17. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003; 98: 1223-31.
18. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003; 238: 528-35.
19. Zapas JL, Coley HC, Beam SL, Brown SD, Jablonski KA, Elias EG. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg 2003; 197: 403-7.
20. Oliveira Filho RS, Ferreira LM, Biasi LJ, Enokihara MM, Paiva GR, Wagner J. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003; 36: 347-50.
21. Rousseau Jr DL, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10: 569-74.
22. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21: 1326-31.
23. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005; 12: 230-5.
24. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12: 449-58.
25. Thompson JF, Shaw HM. Is Sentinel Lymph Node Biopsy Appropriate in Patients With Thin Melanomas: Too Early To Tell? Ann Surg Oncol 2006; 13: 279-81.
26. Starz H, Balda BR. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients. Int J Cancer 2007; 121: 689-93.
27. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008; 143: 892-9.
28. Leiter U, Buettner PG, Eigentler TK,GarbeC. Prognostic factors of thin cutaneousmelanoma: an analysis of the central malignantmelanoma registry of the german dermatological society. J Clin Oncol 2004; 22: 3660-7.
29. Sondak VK, Taylor JM, SabelMS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11: 247-58.
30. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22: 3668-76.
31. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (mm) primary melanoma. Ann Surg Oncol 2003; 10: 558-61.
32. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21: 1057-65.
33. Dewar DJ, Newell B, Green MA, Topping AP, Powell BWEM, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004; 22: 3345-9.
34. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26: 4296-303.
35. Starz HB, Balda BR, Kramer KU, Buchels H, Wang H. A micromorphometry- based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001; 91: 2110-21.
36. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-85.
37. Ollila DW,Ashburn JH,Amos KD, et al. Metastatic melanoma cells in the sentinel node cannot be ignored. J Am Coll Surg2009; 208: 924-9.
38. Cadili A, Smylie M, Danyluk J, Dabbs K. Prediction of nonsentinel lymph node metastasis in malignant melanoma. J Surg Res 2009; 154: 324-9.